Imunon (FRA:CBO0) Cyclically Adjusted Book per Share: €142.50 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CBO0 Imunon Inc FRA:CBO0
37 GF Score
Price €1.30
GF Value €5.35
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Imunon Cyclically Adjusted Book per Share?

Imunon FRA:CBO0 +2.36% 37 Cyclically Adjusted Book per Share is €142.50 as of Jun. 2026. GuruFocus rates FRA:CBO0 with a GF Score™ of 37/100 and a GF Value™ of €5.35 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Imunon's adjusted book value per share for the three months ended in Jun. 2026 was €0.779. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €142.50 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Imunon's average Cyclically Adjusted Book Growth Rate was -61.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -49.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -36.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -26.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Imunon was -2.60% per year. The lowest was -49.10% per year. And the median was -10.50% per year.

As of today (2026-08-18), Imunon's current stock price is €1.30. Imunon's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €142.50. Imunon's Cyclically Adjusted PB Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Imunon was 0.43. The lowest was 0.01. And the median was 0.07.


Imunon  (FRA:CBO0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Imunon's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.30/142.50
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Imunon was 0.43. The lowest was 0.01. And the median was 0.07.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Imunon Cyclically Adjusted Book per Share Related Terms


Imunon Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Imunon's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imunon Cyclically Adjusted Book per Share Chart

Imunon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,387.70 2,125.21 1,231.65 558.70 225.15

Imunon Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 368.91 309.51 225.15 192.99 142.50

FRA:CBO0 vs CVKD, RVPH, PMCB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PB Ratio falls into.


FRA:CBO0
37GF Score
Imunon Inc FRA:CBO0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imunon Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Imunon's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.779/333.9520*333.9520
=0.779

Current CPI (Jun. 2026) = 333.9520.

Imunon Quarterly Data

Book Value per Share CPI Adj_Book
201609 942.000 241.428 1,303.009
201612 579.636 241.432 801.760
201703 285.450 243.801 391.002
201706 197.267 244.955 268.938
201709 103.163 246.819 139.582
201712 256.432 246.524 347.374
201803 210.418 249.554 281.580
201806 180.121 251.989 238.708
201809 140.946 252.439 186.458
201812 191.010 251.233 253.900
201903 189.360 254.202 248.767
201906 155.757 256.143 203.072
201909 125.339 256.759 163.021
201912 110.109 256.974 143.093
202003 97.793 258.115 126.526
202006 126.453 257.797 163.808
202009 85.627 260.280 109.864
202012 73.548 260.474 94.295
202103 120.538 264.877 151.972
202106 120.283 271.696 147.844
202109 114.118 274.310 138.930
202112 111.717 278.802 133.816
202203 95.043 287.504 110.398
202206 81.805 296.311 92.197
202209 76.774 296.808 86.382
202212 48.572 296.797 54.653
202303 35.707 301.836 39.506
202306 28.008 305.109 30.656
202309 23.584 307.789 25.589
202312 17.028 306.746 18.538
202403 10.846 312.332 11.597
202406 4.820 314.175 5.123
202409 6.638 315.301 7.031
202412 3.645 315.605 3.857
202503 0.373 319.799 0.390
202506 1.342 322.561 1.389
202509 1.201 324.800 1.235
202512 1.763 324.054 1.817
202603 0.741 330.213 0.749
202606 0.779 333.952 0.779

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €142.50 mean?
Imunon (FRA:CBO0) has a Cyclically Adjusted Book per Share of €142.50 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Imunon and its competitors.
Is Imunon's Cyclically Adjusted Book per Share too high?
Imunon's current Cyclically Adjusted Book per Share is €142.50. Overall, Imunon has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Imunon's Cyclically Adjusted Book per Share compare to CVKD and RVPH?
Imunon's Cyclically Adjusted Book per Share of €142.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Imunon and its competitors. Imunon's current Cyclically Adjusted Book per Share is €142.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imunon stock overvalued right now?
Based on GuruFocus' analysis, Imunon (FRA:CBO0) is currently considered Possible Value Trap. The stock's GF Value™ is €5.35, compared to a current price of €1.30 — trading 75.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is €142.50. Imunon's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Imunon (FRA:CBO0), the current Cyclically Adjusted Book per Share is €142.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imunon (FRA:CBO0) Overvalued in 2026?

Based on GuruFocus' analysis, Imunon stock appears to be undervalued. The current stock price of €1.30 is trading 75.7% below its estimated GF Value™ of €5.35. GuruFocus considers Imunon to be Possible Value Trap.

Key valuation signals for FRA:CBO0:

  • Cyclically Adjusted Book per Share: €142.50
  • GF Value™: €5.35 vs. price of €1.30 (75.7% below fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the FRA:CBO0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imunon Business Description

Other Exchanges IMNN:USACBO0:Germany
Address 997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
37GF Score

Get the complete analysis for FRA:CBO0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.30
Price
€5.35
GF Value